Immunic (IMUX) Asset Writedowns and Impairment (2018)

Immunic (IMUX) reported Asset Writedowns and Impairment of $1.2 million for Q3 2018.

Immunic (IMUX) Asset Writedowns and Impairment (2018) Analysis & Trends

Immunic (IMUX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $1.2 million in Q3 2018.

For the quarter ending Q3 2018, Asset Writedowns and Impairment changed N/A year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2018 stood at $1.2 million (changed N/A YoY), and the FY2018 full-year result was $1.2 million, changed N/A from the prior year.
Asset Writedowns and Impairment was little changed at $1.2 million in Q3 2018.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.2 million in Q3 2018 to a low of $1.2 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,583.17 Bn	67,582.89 Bn	-
2	Nanobiotix	1,947.22 Bn	1,947.15 Bn	-
3	Akari Therapeutics	1,132.35 Bn	1,132.35 Bn	-
4	BeOne Medicines	473.21 Bn	468.42 Bn	1.35 Bn
5	Vertex Pharmaceuticals	123.29 Bn	116.04 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.05 Bn	61.29 Bn	3.31 Bn
7	Belite Bio	63.09 Bn	63.09 Bn	-
8	Argenx Se	56.63 Bn	51.45 Bn	1.41 Bn
9	Revolution Medicines	37.79 Bn	37.79 Bn	-
10	Immunic	417.39 Mn	417.39 Mn	-

Download Data

Date	Value
Sep 30, 2018	1.22 Mn
Sep 30, 2018	1.22 Mn